The $35K Glatopa price mentioned on the CC for modeling purposes is a 25% discount to Teva’s actual realized price of $47K for US patient taking branded 20mg Copaxone for one year.
The $47K figure comes from multiplying Teva’s list price of $73K by 80% to account for rebates and then multiplying by another 80% to account for non-compliance (i.e. patients who have treatment lapses from not filling their prescriptions).
(MNTA)—TEVA reports $878M of 3Q15 US Copaxone sales (+1% vs 2Q15); 40mg Copaxone comprised for 76% of overall Copaxone volume in Sep 2015, according to IMS:
Market Data 
Markets 
AI
